saniva diagnostics receives approval from the US FDA for its medical product NeuroMex
|
Xlife Sciences AG / Key word(s): Miscellaneous/Regulatory Approval Medical Screening Device Set to Measure Complex Neurocognitive Performance for Early Detection of Severe Neurodegenerative Diseases Such as Parkinson's or Alzheimer's saniva diagnostics, a portfolio company of Xlife Sciences (SIX: XLS), has received the 513(g) approval from the US Food and Drug Administration (FDA) to market and sell its proprietary screening device NeuroMex as a non-regulated medical device in the USA. NeuroMex is a patented screening instrument for cognitive performance and is used to interpret current cognitive performance in patients, which may include those at risk for developing neurodegenerative diseases such as Parkinson's or Alzheimer's disease. Worldwide, more than 55 million people are affected by Parkinson's and Alzheimer's disease (including about seven million in the USA). With the NeuroMex system, saniva diagnostics offers a new solution for healthcare providers and their patients. The detection and interpretation of cognitive function in, for example, Parkinson's sufferers at an early stage enables them to receive targeted treatment at an early stage. Early detection of neurodegenerative diseases with NeuroMex makes it possible to save time in the treatment of people with the disease, improve their quality of life and at the same time reduce costs for the healthcare system. The NeuroMex screening device is non-invasive, fast, and inexpensive and is used to investigate complex neurocognitive performance. It is particularly suitable for use as part of an annual health check-up procedure. The NeuroMex system quantifies an individual’s responsiveness during the one-handed catching of a suddenly falling stick. Equipped with sensors and controlled by software, the stick serves as a measuring device; the stick falls at a point in time that is unpredictable for the patient, making it possible to quantify visual-motor reaction performance. Various parameters are recorded in real-time with sensors. By comparing the individual performance with reference data from healthy individuals and with disease-specific thresholds, the individual neuro-cognitive function can ultimately be determined. At https://sanivadiagnostics.com/neuromex/?lang=en, a video showing how NeuroMex works is available. Jenny Nisser, founder and CEO of saniva diagnostics GmbH, comments: “The launch of NeuroMex in the USA, the largest medical device market in the world, is an important milestone for saniva diagnostics. We are very excited about the progress we have made as a company and part of Xlife Sciences in just three years since our spin-off from Jena University Hospital. Our next goal to work with suitable partners to bring the NeuroMex technology to market worldwide and consequently help the unfortunately rapidly increasing population of people with Parkinson's and dementia by detecting the diseases at an early stage”. Oliver R. Baumann, CEO of Xlife Sciences AG, adds: “We sincerely congratulate the team of our portfolio company saniva diagnostics on this milestone, which is also of relevance for Xlife Sciences. At the same time, we would like to thank the European Regional Development Fund, which supports the research and development activities of saniva diagnostics with funds from the European Union”. Financial calendar Annual Report 2022 April 20, 2023 AGM 2023 June 20, 2023 Half-Year Report 2023 September 21, 2023
Contact Information for journalists: IRF Reputation AG, Valentin Handschin, handschin@irf-reputation.ch Information for investors: Xlife Sciences AG, Dennis Lennartz, dennis.lennartz@xlifesciences.ch Xlife Sciences AG, End of Inside Information |
| Language: | English |
| Company: | Xlife Sciences AG |
| Talacker 35 | |
| 8001 Zürich | |
| Switzerland | |
| Phone: | +41 44 385 84 60 |
| E-mail: | info@xlifesciences.ch |
| Internet: | www.xlifesciences.ch |
| ISIN: | CH0461929603 |
| Valor: | A2PK6Z |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1561107 |
| End of Announcement | EQS News Service |
|
|
1561107 16-Feb-2023 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.